Objectives: To 1) describe patterns of use of high-flow nasal cannula therapy, 2) examine differences between patients started on high-flow nasal cannula and those started on noninvasive ventilation, and 3) explore whether patients who failed high-flow nasal cannula therapy were different from those who did not. Design: Retrospective analysis of data collected prospectively by the Paediatric Intensive Care Audit Network. Setting: All PICUs in the United Kingdom and Republic of Ireland (n = 34). Patients: Admissions to study PICUs (2015PICUs ( -2016 receiving any form of respiratory support at any time during PICU stay.
G reater recognition of the risks of invasive ventilation (IV) have led to increased adoption of noninvasive modes of ventilation such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) in PICUs in the United Kingdom and Republic of Ireland (ROI) as well as internationally (1) (2) (3) . Over the past decade, an alternate mode of noninvasive respiratory support (NRS), heated humidified high-flow nasal cannula (HFNC) therapy, has become popular in critically ill newborns, children, and adults, mainly due to its advantages of greater comfort and therefore better tolerance by patients, easier nursing care, and potential cost savings (4) (5) (6) .
Despite the lack of convincing evidence of its effectiveness from rigorous randomized trials in children (7, 8) , national surveys of practice reveal that many clinicians now consider HFNC as their first-line choice for NRS, both inside and outside the critical care environment (9) (10) (11) . Observational studies, mainly from single centers, demonstrate that there is considerable practice variation in terms of when, why and how clinicians use HFNC in the PICU setting, with the therapy being used in a range of conditions such as asthma, bronchiolitis, pneumonia, cardiac failure, neuromuscular weakness, and recurrent apnoeas as well as for postextubation respiratory support (12) (13) (14) (15) . There is however little-published data describing the patterns of HFNC use at a national or international level.
We aimed to address this evidence gap by analyzing a high quality international clinical database of pediatric intensive care admissions in the United Kingdom and ROI to 1) describe the patterns of use of HFNC (timing, indications for use, and flow rates); 2) examine PICU-and patient-level differences between patients started on HFNC as the first-line mode of NRS and those started on noninvasive ventilation (NIV); and 3) explore whether patients who failed HFNC therapy as firstline NRS were different from those who did not.
METHODS
We analyzed anonymized data prospectively collected by the Paediatric Intensive Care Audit Network (PICANet) clinical audit database. PICANet collects an admission dataset containing clinical and demographic data, as well as information on daily interventions as part of the Paediatric Critical Care Minimum Dataset, from all PICUs in the United Kingdom and ROI. HFNC was included as a daily intervention in PICANet from January 2015. Data quality is ensured by regular training of staff and by local and central validation checks. PICANet has approval to collect personally identifiable data under special circumstances from the Health Research Authority Confidentiality Advisory Group (reference number: PIAG 4-07(c)/2002) and approval from the Trent Medical Research Ethics Committee (reference number: 05/MRE04/17).
Data
We identified all children (< 16 yr old) admitted to study PICUs during a 2-year study period (January 2015 to December 2016) who received any form of respiratory support (IV; NIV such as CPAP, pressure support, or BIPAP; or HFNC) at any point during their admission. We extracted data on the details and timing of each mode of respiratory support used, demographic data (age, gender, and weight), clinical features (primary diagnostic group, main reason for admission, and physiologic variables recorded at admission as part of the Pediatric Index of Mortality [PIM]-2 score) (16) , and key outcomes (length of PICU stay, total length of ventilation, and vital status at PICU discharge).
To fulfill our study aims, we created a restricted dataset in which we included data regarding the first-line respiratory support mode (IV, NIV, or HFNC) and the second-line mode (only if it was started within two calendar days of stopping the first). Admissions were classified into one of nine groups based on a combination of the first and the second respiratory support mode as shown in Figure 1 (IV-no support, IV-NIV, 
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IV-HFNC, NIV-no support, NIV-IV, NIV-HFNC, HFNC-no support, HFNC-NIV, and HFNC-IV). In cases where more than one mode of support was recorded on the same day, we checked the next calendar day to identify the first subsequent form of support to be received alone (e.g., if both IV and NIV were recorded on the day of admission and only IV was recorded on the next calendar day, patients were classified as NIV-IV). Where it was not possible to determine the order in which respiratory support was provided, we excluded those records from further analysis.
Data Analysis
We calculated the number of discrete episodes of HFNC recorded during the entire PICU admission. An episode was defined as a continuous period of HFNC usage followed by at least one calendar day of no receipt of HFNC, irrespective of whether other modes of respiratory support were used. We calculated the median length of time spent on HFNC. We also analyzed the timing of the first recorded respiratory support mode (IV, NIV, and HFNC) in relation to the day of PICU admission.
Using the restricted dataset, we performed three analyses to fulfill our objectives. Analysis 1. We studied the timing of HFNC use ("primary respiratory support": to include the groups HFNC-no support, HFNC-NIV, and HFNC-IV; "postextubation respiratory support": IV-HFNC group), clinical indications ("primary diagnostic group": respiratory, cardiovascular, neurologic, infection, oncology, other; "main primary diagnosis": asthma, bronchiolitis, upper airway obstruction, postoperative, other; "source of admission": same hospital, other hospital, other; "type of admission": planned following surgery, unplanned following surgery, planned other, unplanned other; "physiologic variables at PICU admission": systolic blood pressure, base excess, and serum lactate), and HFNC flow rates (starting flow rate in liters per minute for all patients, and litres per minute per kilogram body weight for children weighing < 10 kg). Analysis 2. To identify possible differences in the use of HFNC or NIV as the first-line NRS mode, we examined PICU characteristics ("unit type": general, cardiac, mixed; "unit size": < 400, 400-800 and > 800 admissions/yr; "emergency admissions rate": low and high, based on the national mean cut-off of 60.6%) as well as patient characteristics (age, gender, weight, primary diagnostic group, main primary diagnosis, source and type of admission, and admission physiologic variables) of children who received HFNC-first versus NIV-first. We also compared their outcomes (length of PICU stay, total length of respiratory support, and PICU mortality). To test the association between the patient characteristics (exposure) and use of HFNC or NIV as first-line NRS mode (outcome) we developed mixed-effects logistic regression models, with the admitting PICU as a random effect. Similarly, to test the association between PICU characteristics (exposure) and use of HFNC or NIV as first-line NRS mode (outcome) we developed logistic regression models. We entered into the models all characteristics that were significantly associated with the outcome in univariate analyses. Analysis 3. We compared patient characteristics and outcomes of children who were commenced on first-line HFNC and failed the therapy (HFNC-NIV and HFNC-IV groups) with those who did not fail HFNC therapy within two calendar days (HFNC-no support) to identify risk factors for HFNC failure. We developed regular as well as mixed-effects logistic regression models to study the association between patient characteristics (exposure) and HFNC failure (outcome) to account for any clustering of data within the admitting PICUs.
Categorical data are reported as number and percentages, and continuous data as means or medians as appropriate. p values of less than 0.05 were considered significant. All analyses were performed using Stata Version 15 (StataCorp, College Station, TX).
RESULTS
During the study period, there were 41,388 admissions recorded in PICANet from 34 PICUs in the United Kingdom and ROI. Our study cohort consisted of 26,423 admissions (63.8%) after we excluded admissions where a tracheostomy was in place (n = 146; 0.4%) or no respiratory support was provided during the admission (n = 10,281, 24.8%), where information on daily interventions was not available (n = 956; 2.3%), where PICUs did not submit HFNC data during the study period (n = 3,334; 8.1%) and admissions unable to be classified by the order in which respiratory support was provided (n = 248; 0.6%). The 26,423 admissions included in the analysis occurred in 20,689 patients. Figure 1 illustrates that a majority of children who received respiratory support received IV as their first recorded mode (n = 21,663; 82.0%), whereas a smaller proportion received NIV (n = 2,680; 10.1%) and HFNC (n = 2,080; 7.9%).
The first-line respiratory support mode (IV, NIV, or HFNC) was started on the day of PICU admission in the vast majority of admissions (95.1%) as shown in Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/PCC/ A817). In total, 5,951 out of 26,423 study subjects (22.5%) received at least one discrete episode of HFNC during their PICU stay (this proportion was 16.1% when all admissions with complete information regarding daily interventions including HFNC and excluding those with a tracheostomy were considered in the denominator [5,951/36,952 admissions]). The majority received just one episode (5,182, 19.6%); some received two episodes (597, 2.3%), and a small proportion received more than two episodes (172, 0.7%). The median length of HFNC use was 2 days (interquartile range [IQR], 1-3 d) for admissions where only one episode of HFNC was used, 4 days (IQR, 3-6 d) for those where two episodes of HFNC were used, and 10 days (IQR, 6-20 d) when over two HFNC episodes were recorded.
Analysis 1: Patterns of HFNC Use
HFNC was started for first-line respiratory support in 2,080 admissions (7.9%) and for postextubation support in 978 out of 21,663 admissions (4.5%) where IV was used as first-line mode. Table 1 illustrates the differences in age, primary diagnostic group, and main primary diagnosis between these two groups: where HFNC was used as primary respiratory support, respiratory conditions accounted for nearly two-thirds of cases, nearly a quarter had bronchiolitis, and over three-quarters of admissions were unplanned medical admissions. In contrast, cardiovascular conditions predominated in the postextubation support group, over half of the group were postoperative patients, and nearly one-half of admissions were planned postsurgical admissions. The median starting flow rate when HFNC was used as primary respiratory support was 8 L/min (IQR, 0-15); in children with a weight of less than 10 kg, the median starting flow rate was 2 L/kg/min (IQR, 1.7-2.5). In the postextubation support group median starting flow rate was 10 L/min (IQR, [8] [9] [10] [11] [12] [13] [14] [15] [16] ; in children less than 10 kg, it was 2 L/kg/ min (IQR, 1.6-2.6). Weight was available only in 709 (34.1%) and 330 (33.7%) admissions respectively. Table 1 . Primary Respiratory Support. Patients who were started on HFNC were significantly younger than those started on NIV (median age, 40 wk; IQR, 12-168 vs 58 wk; IQR, 11-377; p < 0.001), more likely to have a main primary diagnosis of asthma or bronchiolitis and were more likely to be admitted from within the same hospital. As shown in Table 2 , the total duration of respiratory support differed between the two groups (median, 3 d; IQR, 2-6 vs 4 d; IQR, 2-8; p < 0.001) as did length of PICU stay (median, 4 d; IQR, 3-7 vs 5 d; IQR, 3-10). Patients started on HFNC as first-line therapy had a lower crude mortality rate than those started on NIV (2.2% v 3.8%; p < 0.001).
Postextubation Support. Patients started on HFNC after extubation compared with those started on NIV were more likely to have a cardiovascular diagnosis (45.9% vs 38.4%; p < 0.001), more likely to be postoperative cases (54.7% vs 49.9%; p < 0.001), and were more likely to have been admitted to PICU following planned surgery (49.2% vs 45.0%; p < 0.001). There was a significant difference between the groups in terms of mortality (HFNC: 0.5% vs NIV: 1.7%; p = 0.02), total duration of respiratory support (p = 0.02) and length of PICU stay (p < 0.001).
Choice of First-Line NRS. There was significant variation in the choice of HFNC as the first-line mode of NRS based on the admitting PICU (Supplementary There was no difference in terms of the starting HFNC flow rate (median 12 L/min in both groups; p = 0.31). Since there was minimal clustering of data within admitting PICU (intraclass correlation coefficient 0.07), regular logistic regression analysis was used, which showed that independent risk factors for HFNC failure were younger age, primary diagnostic group, unplanned admission, and higher PIM-2 score (Supplementary Table 4 , Supplemental Digital Content 4, http://links.lww. com/PCC/A820).
DISCUSSION
In this retrospective cohort study, we analyzed data from a high-quality clinical database of admissions to PICUs in the United Kingdom and ROI and found that HFNC is used frequently, to provide primary respiratory support as well as support following extubation. We found significant differences between patients in whom HFNC was started for primary respiratory support and those in whom NIV was started, although this practice also varied depending on the characteristics of the admitting PICU, reflecting potential differences in clinician preferences and/or PICU admission thresholds. Nearly a quarter of admissions where HFNC was started for primary respiratory support required to be escalated to other forms of support within two calendar days.
Despite the absence of evidence from randomized trials to support its clinical and cost-effectiveness, HFNC has become a popular means of providing NRS to children, inside and outside the critical care unit (7, 17) . A single-center study from the United States reported that 27% of PICU admissions from a 2-year period (2011-2013) were managed with HFNC, for conditions ranging from asthma, pneumonia, and bronchiolitis to congenital heart disease. HFNC was used most frequently for primary support (73%), although postextubation support was a common indication (16%) (13) . Similarly, experience from one Canadian PICU over a 12-month period suggested that 16% of admissions received HFNC. Congenital heart disease, especially in the postoperative period, was the main patient group in this cohort, and postextubation support was the main indication for HFNC (36%) rather than primary support (31%). Escalation to NIV and/or IV was required in 22% of cases (14) . Our analysis of international data provides roughly similar findings: 22% of study subjects received HFNC, primary respiratory support accounted for 68% of HFNC use, and the rate of escalation to NIV and/or IV was 27%. As a multicentre study, we were also able to demonstrate a significant influence of the admitting PICU characteristics on the patterns of HFNC/NIV use. This finding may have been influenced by differences in unit or clinician preferences resulting from the lack of strong evidence to guide clinical practice, or by unitwise differences in the threshold for PICU admission, which we did not have information on (e.g., NIV-first may appear artificially higher in hospitals where HFNC can be delivered on the wards, but NIV can only be delivered in the PICU).
Our study provides several important findings that may be relevant for future research in this area (18) . First, HFNC has become a common intervention in contemporary PICU practice, being used in nearly a quarter of admissions, and at least as frequently as NIV. Second, there are important differences in the patient groups where HFNC is used for primary support and for postextubation support: respiratory disease, especially bronchiolitis and other respiratory illnesses, is the most common indication for primary support, whereas postoperative cardiac surgery is the most common population in which postextubation support is provided. Third, the median starting flow rate for HFNC is 2 L/kg/min for infants weighing less than 10 kg, indicating that clinicians are potentially choosing to use HFNC as an alternative for CPAP, based on physiologic evidence that a CPAP-effect may be generated at these flow rates (19, 20) . Fourth, in a population of critically ill children with diverse pathologies, the failure rate for HFNC when used as first-line NRS was 27%, with the majority escalating directly to IV (17%), not dissimilar to the failure rate of NIV when used as first-line NRS (28%).
To our knowledge, this is the first detailed international report of clinical practice related to the use of HFNC in the PICU setting. A key strength of our study was the use of a high-quality clinical database covering daily interventions from all PICUs in the United Kingdom and ROI. PICANet uses strict data definitions and trained data collectors to ensure the integrity of data; in addition to real-time validation during data entry, data are subject to independent verification by a trained research nurse during site visits and audit of a random sample of patients. Another key strength of this study was the large sample size and multicentre nature of the dataset that allowed us to confidently explore associations between the use of HFNC and factors relating to the patient and the organization. Limitations to this study include the retrospective analysis, although this may have been ameliorated by high data quality and prospective nature of data collection. Missing data may also have affected our analyses, although the frequency of missing data was generally low, except for admission weight and blood gas variables. We did not include comorbidities in our analysis since missing data were common for this field in the PICANet data. Since PICANet does not collect detailed physiologic data, we were unable to describe the physiologic profile of the groups in terms of respiratory rate, heart rate, and oxygen saturations prior to and after starting NRS, or to explore the reasons for failure in more detail. Similarly, the reasons for clinicians choosing one mode of NRS over another were not available from this dataset. Finally, we analyzed multiple admissions for the same child during the study period as individual admissions, which may have potentially introduced bias due to clustering of data.
CONCLUSIONS
We have shown that the use of HFNC therapy is common in PICUs in the United Kingdom and ROI and that patients started on HFNC for primary respiratory support differ from those started on HFNC for postextubation support. Differences between PICUs in the choice of first-line respiratory support mode (HFNC or NIV) reflect the poor evidence base in this area. Randomized trial evidence is urgently required to guide future intensive care practice.
